

**Table S1.** Baseline patients and tumor characteristics

	All patients (n = 82)	C-SIB (n = 41)	H-SIB (n = 41)	p-value
Age (yr)	50 (43–55)	50 (43–54)	50 (44–56)	0.59
T stage				
T1	52 (63.41)	28 (68.29)	24 (58.54)	0.359
T2	30 (36.59)	13 (31.71)	17 (41.46)	
N stage				
N0	77 (93.9)	38 (92.68)	39 (95.12)	0.644
N1	5 (6.1)	3 (7.32)	2 (4.88)	
Stage grouping (AJCC 7th edition)				
IA	50 (60.98)	27 (65.885)	23 (56.1)	0.411
IB	2 (2.44)	1 (2.44)	1 (2.44)	
IIA	26 (31.71)	10 (24.39)	16 (39.02)	
IIB	4 (4.88)	3 (7.32)	1 (2.44)	
Estrogen receptor				
Positive	27 (32.93)	14 (34.15)	13 (31.71)	0.814
Negative	55 (67.07)	27 (65.85)	28 (68.29)	
Progesterone receptor				
Positive	31 (37.80)	14 (34.15)	17 (41.46)	0.494
Negative	51 (62.2)	27 (65.85)	24 (58.54)	
HER2				
Overexpression	55 (67.07)	31 (75.61)	24 (58.54)	0.236
Negative (0–1+)	12 (14.63)	5 (12.2)	7 (17.07)	
Equivocal (2+)	15 (18.29)	5 (12.2)	10 (24.39)	
Pathology				
Invasive ductal carcinoma	78 (95.12)	38 (92.68)	40 (97.56)	0.616
Invasive lobular carcinoma	1 (1.22)	1 (2.44)	0	
Other invasive carcinomas	3 (3.66)	2 (2.88)	1 (2.44)	
Histologic grade				0.543
1	16 (19.5)	7 (17.1)	9 (22)	
2	43 (52.4)	24 (58.5)	19 (46.3)	
3	23 (28.1)	10 (24.4)	13 (31.7)	

Values are presented as median (range) or number (%).

C-SIB, conventional fractionation with simultaneous integrated boost; H-SIB, hypofractionation with simultaneous integrated boost; AJCC, American Joint Committee on Cancer; HER2, human epidermal growth factor receptor 2.